Drug Trial Radar · NCT04671433
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Dec 4, 2020
Primary completion
Sep 30, 2024
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- MeiraGTx Ocular UK LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
Conditions
- X-Linked Retinitis Pigmentosa
Interventions
Genetic: AAV5-hRKp.RPGRBiological
Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
Genetic: AAV5-hRKp.RPGRBiological
No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 52 in Vision-guided Mobility Assessment (VMA) as Measured by the Ability of the Participant to Navigate Through a VMA MazeTime frame: From Baseline to 52 Weeks
Locations
28 sites in 11 countries. Site status is shown where the registry gives one.
Shiley Eye Institute Jacobs Retina Center
La Jolla, California
Childrens Hospital
Los Angeles, California
Stanford Health Care
Palo Alto, California
VitreoRetinal Associates, PA
Gainesville, Florida
Emory University
Atlanta, Georgia
Massachusetts General Hospital - Center for Celiac Research and Treatment
Boston, Massachusetts
Univ of Michigan Medical Center
Ann Arbor, Michigan
Duke Eye Center
Durham, North Carolina
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania
Retina Consultants of Houston
Bellaire, Texas
UZ Gent
Ghent, Belgium
Hospital For Sick Children
Toronto, Ontario, Canada
Rigshospitalet Glostrup
Glostrup Municipality, Denmark
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Paris, France
Hadassah Medical Center
Jerusalem, Israel
Azienda Ospedaliero Universitaria Careggi
Florence, Italy
Ospedale San Paolo
Milan, Italy
Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli
Naples, Italy
IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS
Roma, Italy
VUMC Amsterdam
Amsterdam, Netherlands
Radboudumc
Nijmegen, Netherlands
Hosp Univ Fund Jimenez Diaz
Madrid, Spain
University Hospital Basel, Eye Clinic/Institute of Molecular and Clinical
Basel, Switzerland
Universite de Lausanne, Hopital ophtalmique Jules-Gonin
Lausanne, Switzerland
NHS Lothian
Edinburgh, United Kingdom
Gartnavel General Hospital
Glasgow, United Kingdom
St James University Hospital
Leeds, United Kingdom
Moorfields Eye Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.